{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-021025","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2023-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.121520+00:00","generated_at":"2026-06-14T06:41:51.080355+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zai Lab partner Novocure's LUNAR Phase 3 trial meets endpoint, shows 3-month OS improvement in metastatic NSCLC","bullets":["TTFields + standard therapies improved median OS from 9.9 to 13.2 months (HR 0.74, p=0.035) in post-platinum metastatic NSCLC.","ICI subgroup median OS was 18.5 vs 10.8 months (HR 0.63, p=0.03), an 8-month improvement.","TTFields was well-tolerated with no added systemic toxicities; only grade 3 device-related AEs.","Novocure plans PMA submission to FDA in H2 2023; Zai Lab will file MAA to China's NMPA thereafter.","Zai Lab has exclusive license to develop/commercialize TTFields in Greater China."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-021025","json":"https://secwatch.observer/filing/0001628280-23-021025.json","markdown":"https://secwatch.observer/filing/0001628280-23-021025.md","text":"https://secwatch.observer/filing/0001628280-23-021025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023021025/0001628280-23-021025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000162828023021025/zlab-20230606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:41:51.080355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}